Q3 EPS Forecast for PDS Biotechnology Boosted by Analyst

PDS Biotechnology Corporation (NASDAQ:PDSB) – HC Wainwright upped their Q3 2026 earnings estimates for PDS Biotechnology in a research report issued to clients and investors on Thursday, August 13th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.12) per share for the quarter, up from their prior estimate of ($0.15). The consensus estimate for PDS Biotechnology’s current full-year earnings is ($0.47) per share. HC Wainwright also issued estimates for PDS Biotechnology’s Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.50) EPS, FY2027 earnings at ($0.43) EPS and FY2028 earnings at ($0.33) EPS.

A number of other analysts also recently weighed in on PDSB. Weiss Ratings raised shares of PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. Wall Street Zen upgraded PDS Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $9.00.

PDS Biotechnology Price Performance

PDSB stock opened at $0.22 on Monday. The company has a quick ratio of 0.57, a current ratio of 0.57 and a debt-to-equity ratio of 2.73. PDS Biotechnology has a 12 month low of $0.21 and a 12 month high of $1.55. The firm has a market cap of $12.33 million, a P/E ratio of -0.34 and a beta of 1.62. The company’s 50-day moving average price is $0.77 and its two-hundred day moving average price is $0.85.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05).

Institutional Investors Weigh In On PDS Biotechnology

Several hedge funds have recently modified their holdings of PDSB. Virtu Financial LLC bought a new stake in PDS Biotechnology during the 4th quarter worth $25,000. Bank of New York Mellon Corp bought a new position in PDS Biotechnology in the second quarter valued at about $60,000. Marshall Wace LLP bought a new position in PDS Biotechnology in the second quarter valued at about $91,000. Jane Street Group LLC acquired a new stake in shares of PDS Biotechnology during the second quarter valued at about $92,000. Finally, Susquehanna International Group LLP boosted its stake in shares of PDS Biotechnology by 603.7% during the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock valued at $95,000 after purchasing an additional 80,937 shares in the last quarter. Institutional investors and hedge funds own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.